A Phase II Study of Pazopanib GW786034, NSC 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Ewing's sarcoma; Liver cancer; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 06 Oct 2019 This trial has been completed in Slovakia, Spain, according to European Clinical Trials Database record.
- 24 Sep 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.
- 29 Aug 2019 Planned End Date changed from 1 Apr 2021 to 26 Nov 2019.